Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances

Asociacion para el Estudio de las Enfermedades Infecciosas276 enrolled

Overview

To evaluate the prevalence of lipodystrophy syndrome in patients receiving currently available antiretroviral drugs, and the prevalence of associated metabolic syndrome in HIV-infected patients with a previous diagnosis of lipodystrophy syndrome, according to the severity of fat accumulation and antiretroviral drug use.

Cross-sectional evaluation of two groups of patients: * patients receiving currently available drugs, in order to determine the changes in fat accumulation by successive dual X-ray absorptiometry (DXA) determinations * patients with previous lipodystrophy syndrome, as evaluated by questionnaire (HOPS) and total body dual X-ray absorptiometry (DXA), in order to determine the prevalence of hypertension, low high density lipoprotein (HDL)-cholesterol, glucose disturbance (insulin resistance or diabetes), fat accumulation (waist circumference) and hypertriglyceridemia. The prevalence of Metabolic syndrome will be evaluated according to the different definitions (IDF, NCEP-ATP III, WHO).

Study Type

OBSERVATIONAL

Enrollment

276

Conditions

Lipodystrophy Metabolic Syndrome

Interventions

Evaluation of metabolic syndromeOTHER

Evaluation and analytical determinations of the different components of the syndrome

Evaluation of changes in fat by DXA while on current therapyOTHER

Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * HIV infection * Older than 18 years * Receiving first or second antiretroviral regimen or * Previous evaluation and classification of lipodystrophy syndrome Exclusion Criteria: * Pregnancy * Diagnosis of hypothyroidism, Cushing's syndrome or prolonged intake of corticosteroids or hormones before inclusion * Patients who had received antiretroviral drugs known to produce fat disturbances (for lipodystrophy prevalence objective)

Locations (1)

Ramon y Cajal Hospital

Madrid, Spain

Outcomes

Primary Outcomes

Prevalence of metabolic syndrome as defined by the NCEP-ATP III (National Cholesterol Education Programme-Adult Treatment Panel III)

Prevalence of the different components of this syndrome: Abdominal obesity: waist circumference ≥102 cm in men and ≥88 cm in women, hypertriglyceridemia: ≥150 mg/dl (1.695 mmol/l), low HDL-C: \<40 mg/dl in men and \<50 mg/dl in women, high blood pressure (BP): \>130/85 mmHg, and high fasting glucose: \>110 mg/dl.

Time frame: 3 months

Prevalence of lipodystrophy syndrome as defined by changes in fat by DXA

Comparison of changes in visceral and subcutaneous fat during current antiretroviral therapy for patients receiving current antiretroviral regimens and who never received thymidine analogues, didanosine, lopinavir, indinavir, or nelfinavir.

Time frame: 6 meses

Secondary Outcomes

Value of dual X-ray absorptiometry (DXA) in predicting the development of lipodystrophy and metabolic syndrome

Correlations of visceral fat by DXA with fat accumulation, hypertension, diabetes or hypertriglyeceridemia

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.